menu
    • menu
    [{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VB517","moa":"c-KIT","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty Nobility \/ ValenzaBio"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novelty Nobility \/ Novelty Nobility","highestDevelopmentStatusID":"14","companyTruncated":"Novelty Nobility \/ Novelty Nobility"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Novelty Nobility \/ GC Biopharma","highestDevelopmentStatusID":"14","companyTruncated":"Novelty Nobility \/ GC Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Novelty Nobility

    Menu

    Novelty Nobility

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novelty Nobility

                            South Korea arrow
                            CPhI India 2024
                            Not Confirmed

                            Novelty Nobility

                            South Korea arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Recipient : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GC Biopharma, Novelty Nobility Partner on Geographic Atrophy R&D

                            Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Recipient : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novelty Nobility

                            South Korea arrow
                            CPhI India 2024
                            Not Confirmed

                            Novelty Nobility

                            South Korea arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Sponsor : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GC Biopharma And Novelty Nobility Team Up for Geographic Atrophy R&D

                            Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Sponsor : GC Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novelty Nobility

                            South Korea arrow
                            CPhI India 2024
                            Not Confirmed

                            Novelty Nobility

                            South Korea arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VB517

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : ValenzaBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Mo...

                            Details : VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. ValenzaBio plans to initiate clinical studies of VB517 in 2023.

                            Brand Name : VB517

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 15, 2022

                            Lead Product(s) : VB517

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : ValenzaBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth